• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Patient taking Gilenya develops rare disease









All the ms drugs are scary. I bet the longer Gilenya is on the market, the more "rare diseases" pop up. When you take something that completely suppresses the immune system, people are bound to die. Very scary!!
 








I guess the phrase "reversably sequesters lymphocytes" may be inaccurate Mr. Gilenya rep. Start looking at apoptosis of lymphocytes once sequestered in the lymph node. Troubling!
 




































All due time...investigations are taking place. Medicines don't just "get pulled" There's a process and it takes a while to gather all the facts. Don't worry one day it won't be here.